Erlanger Cardiology completed the first in Chattanooga concomitant left atrial appendage closure (LAAC) and cardiac ablation ...

During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed ...

A combination of Imbruvica and venetoclax showed significantly prolonged progression-free survival in patients with untreated ...

The first-in-human trial is taking place at Na Homolce hospital in Prague, Czechia, and will treat up to 50 patients.

The China 3D cardiac mapping market has showcased significant growth, with its valuation increasing from $55.55 million in 2019 to a projected $150.59 million by 2027. This report offers a detailed ...

In the U.S., atrial fibrillation (AF), a heart condition that causes an irregular heartbeat in the upper chambers of the ...

Two posters presented at the 2024 American Society of Hematology meeting evaluated overall survival and cost-offset of ...

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today ...

In patients with atrial fibrillation, a resting heart rate of 80 bpm or higher is associated with increased risk for mortality.

Pulse Biosciences, Inc. , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablationtm (nano-PFA or nsPFAtm) technology, today announced a new publication in the Journal of ...

The global electrophysiology market is poised for significant growth, projected to expand from USD 4,350.7 billion in 2024 to USD 9,078.4 billion by 2034, at a robust CAGR of 7.6%. This remarkable ...